Recent Research Trends against Skin Carcinoma - An Overview


Cite item

Full Text

Abstract


Skin cancer is a prevalent and sometimes lethal cancer that affects a wide range of people. UV radiation exposure is the main cause of skin cancer. Immunosuppression, environmental factors, and genetic predisposition are other contributing variables. Fair-skinned people and those with a history of sunburns or severe sun exposure are more likely to experience this condition. Melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) are the three main forms. Melanoma poses a bigger hazard because of its tendency for metastasis, while SCC and BCC have limited metastatic potential. Genetic mutations and changes to signalling pathways such as p53 and MAPK are involved in pathogenesis. Early diagnosis is essential, and molecular testing, biopsy, dermoscopy, and visual inspection can all help. In addition to natural medicines like curcumin and green tea polyphenols, treatment options include immunotherapy, targeted therapy, radiation, surgery, and chemotherapy. Reducing the incidence of skin cancer requires preventive actions, including sun protection and early detection programs. An overview of skin cancers, including their forms, pathophysiology, diagnosis, and treatment, highlighting herbal therapy, is given in this review.

About the authors

Kamya Varshney

, Noida Institute of Engineering and Technology (Pharmacy Institute)

Email: info@benthamscience.net

Rupa Mazumder

Pharmacy Institute, Noida Institute of Engineering and Technology

Author for correspondence.
Email: info@benthamscience.net

Anjna Rani

Pharmacy Institute, Noida Institute of Engineering and Technology (Pharmacy Institute)

Email: info@benthamscience.net

Rashmi Mishra

Department of Biotechnology, Noida Institute of Engineering and Technology

Email: info@benthamscience.net

Navneet Khurana

School of Pharmaceutical Sciences, Lovely Professional University

Email: info@benthamscience.net

References

  1. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: Recent insights into skin immune function. Immunity 2011; 35(6): 857-69. doi: 10.1016/j.immuni.2011.12.003 PMID: 22195743
  2. Kashyap MP, Sinha R, Mukhtar MS, Athar M. Epigenetic regulation in the pathogenesis of non-melanoma skin cancer. Semin Cancer Biol 2022; 83: 36-56. doi: 10.1016/j.semcancer.2020.11.009 PMID: 33242578
  3. Didona D, Paolino G, Bottoni U, Cantisani C. Nonmelanoma skin cancer pathogenesis overview. Biomedicines 2018; 6(1): 6. doi: 10.3390/biomedicines6010006 PMID: 29301290
  4. Cockerell CJ. The pathology of melanoma. Dermatol Clin 2012; 30(3): 445-68. doi: 10.1016/j.det.2012.04.007 PMID: 22800551
  5. Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin cancer: Epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther 2017; 7(S1) (Suppl. 1): 5-19. doi: 10.1007/s13555-016-0165-y PMID: 28150105
  6. Fernandes AR, Santos AC, Sanchez-Lopez E, et al. Neoplastic multifocal skin lesions: Biology, etiology, and targeted therapies for nonmelanoma skin cancers. Skin Pharmacol Physiol 2018; 31(2): 59-73. doi: 10.1159/000479529 PMID: 29262420
  7. Rojas KD, Perez ME, Marchetti MA, Nichols AJ, Penedo FJ, Jaimes N. Skin cancer: Primary, secondary, and tertiary prevention. Part II. J Am Acad Dermatol 2022; 87(2): 271-88. doi: 10.1016/j.jaad.2022.01.053 PMID: 35176398
  8. Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006; 55(5): 741-60. doi: 10.1016/j.jaad.2005.08.063 PMID: 17052479
  9. Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol 2017; 76(4): 639-647.e2. doi: 10.1016/j.jaad.2016.09.047 PMID: 27876302
  10. Balda A, Wani I, Roohi TF, et al. Psoriasis and skin cancer – Is there a link? Int Immunopharmacol 2023; 121: 110464. doi: 10.1016/j.intimp.2023.110464 PMID: 37390565
  11. Fahradyan A, Howell A, Wolfswinkel E, Tsuha M, Sheth P, Wong A. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare 2017; 5(4): 82. doi: 10.3390/healthcare5040082 PMID: 29104226
  12. Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: The pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 2012; 122(2): 464-72. doi: 10.1172/JCI57415 PMID: 22293185
  13. Kasper M, Jaks V, Hohl D, Toftgård R. Basal cell carcinoma - molecular biology and potential new therapies. J Clin Invest 2012; 122(2): 455-63. doi: 10.1172/JCI58779 PMID: 22293184
  14. Sánchez-Danés A, Blanpain C. Deciphering the cells of origin of squamous cell carcinomas. Nat Rev Cancer 2018; 18(9): 549-61. doi: 10.1038/s41568-018-0024-5 PMID: 29849070
  15. Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: A review of high-risk and metastatic disease. Am J Clin Dermatol 2016; 17(5): 491-508. doi: 10.1007/s40257-016-0207-3 PMID: 27358187
  16. Farberg AS, Marson JW, Glazer A, et al. Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: Consensus from the skin cancer prevention working group. Dermatol Ther 2022; 12(4): 807-23. doi: 10.1007/s13555-022-00709-x PMID: 35353350
  17. Cives M, Mannavola F, Lospalluti L, et al. Non-melanoma skin cancers: Biological and clinical features. Int J Mol Sci 2020; 21(15): 5394. doi: 10.3390/ijms21155394 PMID: 32751327
  18. Di Stefani A, Chimenti S. Societa italiana di dermatologia e sifilografia. Basal cell carcinoma: Clinical and pathological features. Soc Ital Dermat Sifilografia 2015; 150(4): 385-91.
  19. Abbas O, Richards JE, Mahalingam M. Fibroblast-activation protein: A single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Mod Pathol 2010; 23(11): 1535-43. doi: 10.1038/modpathol.2010.142 PMID: 20711172
  20. Betti R, Menni S, Radaelli G, Bombonato C, Crosti C. Micronodular basal cell carcinoma: A distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol 2010; 37(7): 611-6. doi: 10.1111/j.1346-8138.2009.00772.x PMID: 20629826
  21. Tan CZ, Rieger KE, Sarin KY. Basosquamous carcinoma: Controversy, advances, and future directions. Dermatol Surg 2017; 43(1): 23-31. doi: 10.1097/DSS.0000000000000815 PMID: 27340741
  22. Dennis LK, White E, Lee JAH. Recent cohort trends in malignant melanoma by anatomic site in the United States. Cancer Causes Control 1993; 4(2): 93-100. doi: 10.1007/BF00053149 PMID: 8481498
  23. Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer 2022; 22(1): 836. doi: 10.1186/s12885-022-09940-3 PMID: 35907848
  24. Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet 2018; 392(10151): 971-84. doi: 10.1016/S0140-6736(18)31559-9 PMID: 30238891
  25. Evans RD, Kopf AW, Lew RA, et al. Risk factors for the development of malignant melanoma: Review of case-control studies. J Dermatol Surg Oncol 1988; 14(4): 393-408. doi: 10.1111/j.1524-4725.1988.tb03373.x PMID: 3280634
  26. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25(6): 459-63. doi: 10.1046/j.1365-2230.2000.00693.x PMID: 11044179
  27. Roomi MW, Roomi NW, Kalinovsky T, Ivanov V, Rath M, Niedzwiecki A. Inhibition of 7,12-dimethylbenzanthracene-induced skin tumors by a nutrient mixture. Med Oncol 2008; 25(3): 333-40. doi: 10.1007/s12032-008-9041-7 PMID: 18204975
  28. Pinchuk I, Shoval H, Dotan Y, Lichtenberg D. Evaluation of antioxidants: Scope, limitations and relevance of assays. Chem Phys Lipids 2012; 165(6): 638-47. doi: 10.1016/j.chemphyslip.2012.05.003 PMID: 22721987
  29. The Fitzpatrick Skin Type Classification Scale. 2008. Available from: https://www.skininc.com/science/physiology/article/ 21882228/the-fitzpatrick-skin-type-classification-scale(accessed on 13-6-2024)
  30. Fitzpatrick TB. Ultraviolet-induced pigmentary changes: Benefits and hazards. Curr Probl Dermatol 1986; 15: 25-38. doi: 10.1159/000412090 PMID: 3512179
  31. Perez L. Diagnosis and management of nonmelanoma skin cancer. Osteopath Family Phys 2020; 12(3): 30-4. doi: 10.33181/12032
  32. Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept 2017; 7(2): 1-6. doi: 10.5826/dpc.0702a01 PMID: 28515985
  33. Lewis KG, Weinstock MA. Nonmelanoma skin cancer mortality (1988-2000): The Rhode Island follow-back study. Arch Dermatol 2004; 140(7): 837-42. doi: 10.1001/archderm.140.7.837 PMID: 15262694
  34. Doran CM, Ling R, Byrnes J, et al. Benefit cost analysis of three skin cancer public education mass-media campaigns implemented in New South Wales, Australia. PLoS One 2016; 11(1): e0147665. doi: 10.1371/journal.pone.0147665 PMID: 26824695
  35. Reichrath J, Saternus R, Vogt T. Endocrine actions of vitamin D in skin: Relevance for photocarcinogenesis of non-melanoma skin cancer, and beyond. Mol Cell Endocrinol 2017; 453: 96-102. doi: 10.1016/j.mce.2017.05.001 PMID: 28526240
  36. Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: A case-control study. Eur J Dermatol 2017; 27(4): 382-5. doi: 10.1684/ejd.2017.3025 PMID: 28468736
  37. Cummings SR, Tripp MK, Herrmann NB. Approaches to the prevention and control of skin cancer. Cancer Metastasis Rev 1997; 16(3/4): 309-27. doi: 10.1023/A:1005804328268 PMID: 9433642
  38. Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J. UV-induced squamous cell carcinoma - a role for antiapoptotic signalling pathways. Br J Dermatol 2009; 161(s3) (Suppl. 3): 107-15. doi: 10.1111/j.1365-2133.2009.09458.x PMID: 19775366
  39. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: Accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156(s3) (Suppl. 3): 1-7. doi: 10.1111/j.1365-2133.2007.07861.x PMID: 17488399
  40. Urbach F, Forbes PD, Davies RE, Berger D. Cutaneous photobiology: Past, present and future. J Invest Dermatol 1976; 67(1): 209-24. doi: 10.1111/1523-1747.ep12513042 PMID: 778294
  41. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41(1): 45-60. doi: 10.1016/j.ejca.2004.10.016 PMID: 15617990
  42. Miligi L. Ultraviolet radiation exposure: Some observations and considerations, focusing on some italian experiences, on cancer risk, and primary prevention. Environments 2020; 7(2): 10. doi: 10.3390/environments7020010
  43. Tyrrell RM. Induction of pyrimidine dimers in bacterial DNA by 365 nm radiation. Photochem Photobiol 1973; 17(1): 69-73. doi: 10.1111/j.1751-1097.1973.tb06334.x PMID: 4568994
  44. Kong Y, Jiang J, Huang Y, et al. Endoplasmic reticulum stress in melanoma pathogenesis and resistance. Biomed Pharmacother 2022; 155: 113741. doi: 10.1016/j.biopha.2022.113741 PMID: 36271543
  45. Kavasi RM, Neagu M, Constantin C, et al. Matrix effectors in the pathogenesis of keratinocyte-derived carcinomas. Front Med 2022; 9: 879500. doi: 10.3389/fmed.2022.879500 PMID: 35572966
  46. Bald T, Quast T, Landsberg J, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014; 507(7490): 109-13. doi: 10.1038/nature13111 PMID: 24572365
  47. Mohammad T, Morrison H, HogenEsch H. Urocanic acid photochemistry and photobiology. Photochem Photobiol 1999; 69(2): 115-35. doi: 10.1111/j.1751-1097.1999.tb03264.x PMID: 10048307
  48. Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell 2016; 29(6): 783-803. doi: 10.1016/j.ccell.2016.05.005 PMID: 27300434
  49. Walko G, Woodhouse S, Pisco AO, et al. A genome-wide screen identifies YAP/WBP2 interplay conferring growth advantage on human epidermal stem cells. Nat Commun 2017; 8(1): 14744. doi: 10.1038/ncomms14744 PMID: 28332498
  50. Howard A, Bojko J, Flynn B, Bowen S, Jungwirth U, Walko G. Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers. Exp Dermatol 2022; 31(10): 1477-99. doi: 10.1111/exd.14655 PMID: 35913427
  51. Gallagher RP, Bajdik CD, Fincham S, et al. Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 1996; 5(6): 419-24. PMID: 8781736
  52. Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett 2012; 327(1-2): 48-60. doi: 10.1016/j.canlet.2011.12.012 PMID: 22182453
  53. Asgari MM, Kiviat NB, Critchlow CW, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008; 128(6): 1409-17. doi: 10.1038/sj.jid.5701227 PMID: 18185530
  54. Bavinck JNB, Plasmeijer EI, Feltkamp MCW. β-papillomavirus infection and skin cancer. J Invest Dermatol 2008; 128(6): 1355-8. doi: 10.1038/jid.2008.123 PMID: 18478011
  55. Aldabagh B, Angeles JGC, Cardones AR, Arron ST. Cutaneous squamous cell carcinoma and human papillomavirus: Is there an association? Dermatol Surg 2013; 39(1): 1-23. doi: 10.1111/j.1524-4725.2012.02558.x PMID: 22928516
  56. Lan YJ, Chen H, Chen JQ, Lei QH, Zheng M, Shao ZR. Immunolocalization of vimentin, keratin 17, Ki-67, involucrin, β- catenin and E-cadherin in cutaneous squamous cell carcinoma. Pathol Oncol Res 2014; 20(2): 263-6. doi: 10.1007/s12253-013-9690-5 PMID: 23999979
  57. Shen J, Abel EL, Riggs PK, et al. Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice. Carcinogenesis 2012; 33(11): 2208-19. doi: 10.1093/carcin/bgs213 PMID: 22782996
  58. Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154(3): 498-504. doi: 10.1111/j.1365-2133.2005.07021.x PMID: 16445782
  59. Yesantharao P, Wang W, Ioannidis NM, Demehri S, Whittemore AS, Asgari MM. Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system. Hum Immunol 2017; 78(4): 327-35. doi: 10.1016/j.humimm.2017.02.002 PMID: 28185865
  60. Glover MT, Brown J, Navarrete C, et al. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. Eur J Cancer 1993; 29(4): 520-4. doi: 10.1016/S0959-8049(05)80143-1 PMID: 8435203
  61. Chen AC, Halliday GM, Damian DL. Non-melanoma skin cancer: Carcinogenesis and chemoprevention. Pathology 2013; 45(3): 331-41. doi: 10.1097/PAT.0b013e32835f515c PMID: 23478234
  62. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005; 571(1-2): 185-205. doi: 10.1016/j.mrfmmm.2004.06.059 PMID: 15748647
  63. Schwarz A, Noordegraaf M, Maeda A, Torii K, Clausen BE, Schwarz T. Langerhans cells are required for UVR-induced immunosuppression. J Invest Dermatol 2010; 130(5): 1419-27. doi: 10.1038/jid.2009.429 PMID: 20090769
  64. Florence MEB, Massuda JY, Bröcker EB, Metze K, Cintra ML, de Souza EM. Angiogenesis in the progression of cutaneous squamous cell carcinoma: An immunohistochemical study of endothelial markers. Clinics (São Paulo) 2011; 66(3): 465-8. doi: 10.1590/S1807-59322011000300018 PMID: 21552674
  65. Paulitschke V, Gerner C, Hofstätter E, et al. Proteome profiling of keratinocytes transforming to malignancy. Electrophoresis 2015; 36(4): 564-76. doi: 10.1002/elps.201400309 PMID: 25395074
  66. Villiotou V, Deliconstantinos G. Nitric oxide, peroxynitrite and nitroso-compounds formation by ultraviolet A (UVA) irradiated human squamous cell carcinoma: Potential role of nitric oxide in cancer prognosis. Anticancer Res 1995; 15(3): 931-42. PMID: 7544092
  67. Maeda A, Nakata M, Yasuda K, et al. Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis. Oncol Rep 2013; 29(1): 39-44. doi: 10.3892/or.2012.2075 PMID: 23064377
  68. Ruiz MT, Biselli PM, Maniglia JV, Pavarino-Bertelli EC, Goloni-Bertollo EM. Genetic variability of vascular endothelial growth factor and prognosis of head and neck cancer in a Brazilian population. Braz J Med Biol Res 2010; 43(2): 127-33. doi: 10.1590/S0100-879X2009007500036 PMID: 20098841
  69. Guo D, Wang Q, Li C, Wang Y, Chen X. VEGF stimulated the angiogenesis by promoting the mitochondrial functions. Oncotarget 2017; 8(44): 77020-7. doi: 10.18632/oncotarget.20331 PMID: 29100366
  70. Woo YR, Cho SH, Lee JD, Kim HS. The human microbiota and skin cancer. Int J Mol Sci 2022; 23(3): 1813. doi: 10.3390/ijms23031813 PMID: 35163734
  71. Wood DLA, Lachner N, Tan JM, et al. A natural history of actinic keratosis and cutaneous squamous cell carcinoma microbiomes. MBio 2018; 9(5): e01432-18. doi: 10.1128/mBio.01432-18 PMID: 30301852
  72. Nakatsuji T, Chen TH, Butcher AM, et al. A commensal strain of Staphylococcus epidermidis protects against skin neoplasia. Sci Adv 2018; 4(2): eaao4502. doi: 10.1126/sciadv.aao4502 PMID: 29507878
  73. Glatthardt T, Campos JCM, Chamon RC, et al. Small molecules produced by commensal Staphylococcus epidermidis disrupt formation of biofilms by Staphylococcus aureus. Appl Environ Microbiol 2020; 86(5): e02539-19. doi: 10.1128/AEM.02539-19 PMID: 31862721
  74. Li H, Goh BN, Teh WK, et al. Skin commensal Malassezia globosa secreted protease attenuates Staphylococcus aureus biofilm formation. J Invest Dermatol 2018; 138(5): 1137-45. doi: 10.1016/j.jid.2017.11.034 PMID: 29246799
  75. Haenssle HA, Fink C, Schneiderbauer R, et al. Man against machine: Diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Ann Oncol 2018; 29(8): 1836-42. doi: 10.1093/annonc/mdy166 PMID: 29846502
  76. Khan MQ, Hussain A, Rehman SU, et al. Classification of melanoma and nevus in digital images for diagnosis of skin cancer. IEEE Access 2019; 7: 90132-44. doi: 10.1109/ACCESS.2019.2926837
  77. Kousis I, Perikos I, Hatzilygeroudis I, Virvou M. Deep learning methods for accurate skin cancer recognition and mobile application. Electronics (Basel) 2022; 11(9): 1294. doi: 10.3390/electronics11091294
  78. Poser I, Tatzel J, Kuphal S, Bosserhoff AK. Functional role of MIA in melanocytes and early development of melanoma. Oncogene 2004; 23(36): 6115-24. doi: 10.1038/sj.onc.1207797 PMID: 15208686
  79. Rawson RV, Vergara IA, Stretch JR, et al. Representativeness of initial skin biopsies showing pure desmoplastic melanoma: Implications for management. Pathology 2023; 55(2): 214-22. doi: 10.1016/j.pathol.2022.12.346 PMID: 36646575
  80. Hogarty DT, Su JC, Phan K, et al. Artificial intelligence in dermatology-where we are and the way to the future: A review. Am J Clin Dermatol 2020; 21(1): 41-7. doi: 10.1007/s40257-019-00462-6 PMID: 31278649
  81. Jahn AS, Navarini AA, Cerminara SE, et al. Over-detection of melanoma-suspect lesions by a CE-certified smartphone app: Performance in comparison to dermatologists, 2D and 3D convolutional neural networks in a prospective data set of 1204 pigmented skin lesions involving patients’ perception. Cancers (Basel) 2022; 14(15): 3829. doi: 10.3390/cancers14153829 PMID: 35954491
  82. Pawlik L, Morgenroth S, Dummer R. Recent progress in the diagnosis and treatment of melanoma and other skin cancers. Cancers (Basel) 2023; 15(6): 1824. doi: 10.3390/cancers15061824 PMID: 36980709
  83. Żółkiewicz J, Sławińska M, Maińska U, Nowicki RJ, Sobjanek M, Thomas L. Dermoscopy of umbilical lesions-A systematic review. J Clin Med 2024; 13(6): 1790. doi: 10.3390/jcm13061790 PMID: 38542014
  84. Farady I, Furqon EN, Kuo C-C, Jan Y-K, Lin C-Y. Pseudo Skin Image Generator (PSIG-Net): Ambiguity-free sample generation and outlier control for skin lesion classification. Biomed Signal Process Control 2024; 93: 106112. doi: 10.1016/j.bspc.2024.106112
  85. Schuh S, Ruini C, Perwein MKE, et al. Line-field confocal optical coherence tomography: A new tool for the differentiation between nevi and melanomas? Cancers (Basel) 2022; 14(5): 1140. doi: 10.3390/cancers14051140 PMID: 35267448
  86. Viegas J, Sarmento B. Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research. Adv Drug Deliv Rev 2024; 208: 115295. doi: 10.1016/j.addr.2024.115295 PMID: 38527625
  87. Trager MH, Geskin LJ, Samie FH, Liu L. Biomarkers in melanoma and non-melanoma skin cancer prevention and risk stratification. Exp Dermatol 2022; 31(1): 4-12. doi: 10.1111/exd.14114 PMID: 32415889
  88. Bosserhoff AK. Melanoma inhibitory activity (MIA): An important molecule in melanoma development and progression. Pigment Cell Res 2005; 18(6): 411-6. doi: 10.1111/j.1600-0749.2005.00274.x PMID: 16280006
  89. Vučetić B, Rogan SA, Hrabač P, et al. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res 2008; 18(3): 201-7. doi: 10.1097/CMR.0b013e3283021929 PMID: 18477894
  90. Shalhout SZ, Kaufman HL, Emerick KS, Miller DM. Immunotherapy for nonmelanoma skin cancer: Facts and hopes. Clin Cancer Res 2022; 28(11): 2211-20. doi: 10.1158/1078-0432.CCR-21-2971 PMID: 35121622
  91. Carreira B, Acúrcio RC, Matos AI, et al. Nanomedicines as multifunctional modulators of melanoma immune microenvironment. Adv Ther (Weinh) 2021; 4(1): 2000147. doi: 10.1002/adtp.202000147
  92. Azhar F, Naureen H, Shahnaz G, et al. Development of chitosan based β-carotene mucoadhesive formulation for skin cancer treatment. Int J Biol Macromol 2023; 253(Pt 1): 126659. doi: 10.1016/j.ijbiomac.2023.126659 PMID: 37660856
  93. Conforti C, Corneli P, Harwood C, Zalaudek I. Evolving role of systemic therapies in non-melanoma skin cancer. Clin Oncol (R Coll Radiol) 2019; 31(11): 759-68. doi: 10.1016/j.clon.2019.08.011 PMID: 31522944
  94. Tagliaferri L, Ciardo FG. Non-melanoma skin cancer treated by contact high-dose-rate radiotherapy (brachytherapy): A mono-institutional series and literature review. In Vivo 2021; 35(4): 2313-9. doi: 10.21873/invivo.12505 PMID: 34182511
  95. McDaniel WE. Therapy for basal cell epitheliomas by curettage only. Further study. Arch Dermatol 1983; 119(11): 901-3. doi: 10.1001/archderm.1983.01650350029009 PMID: 6639109
  96. Kauvar ANB, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: Squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 2015; 41(11): 1214-40. doi: 10.1097/DSS.0000000000000478 PMID: 26445288
  97. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin. J Photochem Photobiol B 1990; 6(1-2): 143-8. doi: 10.1016/1011-1344(90)85083-9 PMID: 2121931
  98. Rhodes LE, de Rie M, Enström Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs. surgery for nodular basal cell carcinoma: Results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140(1): 17-23. doi: 10.1001/archderm.140.1.17 PMID: 14732655
  99. Suárez-Valladares MJ, Rodriguez-Prieto MÁ, Serra-Llusà R. Penetration of 630 nm laser and 5-aminolevulinic acid in tissue with intralesional photodynamic therapy. Photodiagn Photodyn Ther 2016; 16: 166-8. doi: 10.1016/j.pdpdt.2016.09.006 PMID: 27645917
  100. Lui H, Hobbs L, Tope WD, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: Two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 2004; 140(1): 26-32. doi: 10.1001/archderm.140.1.26 PMID: 14732656
  101. Dąbrowski JM, Arnaut LG. Photodynamic therapy (PDT) of cancer: From local to systemic treatment. Photochem Photobiol Sci 2015; 14(10): 1765-80. doi: 10.1039/c5pp00132c PMID: 26219737
  102. Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen’s disease and squamous cell carcinoma. Br J Dermatol 2008; 159(1): 137-44. doi: 10.1111/j.1365-2133.2008.08593.x PMID: 18489606
  103. Griffin L, Lear J. Photodynamic therapy and non-melanoma skin cancer. Cancers (Basel) 2016; 8(10): 98. doi: 10.3390/cancers8100098 PMID: 27782094
  104. Jalian HR, Avram MM, Stankiewicz KJ, Shofner JD, Tannous Z. Combined 585 nm pulsed-dye and 1,064 nm Nd:YAG lasers for the treatment of basal cell carcinoma. Lasers Surg Med 2014; 46(1): 1-7. doi: 10.1002/lsm.22201 PMID: 24272664
  105. Soleymani T, Abrouk M, Kelly KM. An analysis of laser therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2017; 43(5): 615-24. doi: 10.1097/DSS.0000000000001048 PMID: 28195845
  106. Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014; 32(8): 745-51. doi: 10.1200/JCO.2013.49.9525 PMID: 24493717
  107. Kwon S, Dong ZM, Wu PC. Sentinel lymph node biopsy for high- risk cutaneous squamous cell carcinoma: Clinical experience and review of literature. World J Surg Oncol 2011; 9(1): 80. doi: 10.1186/1477-7819-9-80 PMID: 21771334
  108. Benkhaled S, Van Gestel D, Gomes da Silveira Cauduro C, Palumbo S, Marmol V, Desmet A. The state of the art of radiotherapy for non-melanoma skin cancer: A review of the literature. Front Med 2022; 9: 913269. doi: 10.3389/fmed.2022.913269 PMID: 35833108
  109. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373(17): 1618-26. doi: 10.1056/NEJMoa1506197 PMID: 26488693
  110. Abramson AK, Krasny MJ, Goldman GD. Tangential shave removal of basal cell carcinoma. Dermatol Surg 2013; 39(3): 387-92. doi: 10.1111/dsu.12106 PMID: 23279298
  111. Ghareeb ER, Dulmage BO, Vargo JA, Balasubramani GK, Beriwal S. Underutilization of Mohs micrographic surgery for less common cutaneous malignancies in the United States. Dermatol Surg 2016; 42(5): 653-62. doi: 10.1097/DSS.0000000000000705 PMID: 27054447
  112. Schell AE, Russell MA, Park SS. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg 2013; 15(5): 337-43. doi: 10.1001/jamafacial.2013.1011 PMID: 23744451
  113. Krähn G, Leiter U, Kaskel P, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001; 37(2): 251-9. doi: 10.1016/S0959-8049(00)00364-6 PMID: 11166154
  114. Amaral T, Garbe C. Non-melanoma skin cancer: New and future synthetic drug treatments. Expert Opin Pharmacother 2017; 18(7): 689-99. doi: 10.1080/14656566.2017.1316372 PMID: 28414587
  115. Micali G, Lacarrubba F, Nasca MR, Ferraro S, Schwartz RA. Topical pharmacotherapy for skin cancer: Part II. Clinical applications. J Am Acad Dermatol 2014; 70(6): 979.
  116. Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-Fluorouracil. J Cutan Med Surg 2003; 7(2): 101-5. doi: 10.1177/120347540300700201 PMID: 12447619
  117. Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines. Eur J Cancer 2019; 118: 10-34. doi: 10.1016/j.ejca.2019.06.003 PMID: 31288208
  118. Danial C, Sarin KY, Oro AE, Chang ALS. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res 2016; 22(6): 1325-9. doi: 10.1158/1078-0432.CCR-15-1588 PMID: 26546616
  119. Cortes JE, Douglas Smith B, Wang ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 2018; 93(11): 1301-10. doi: 10.1002/ajh.25238 PMID: 30074259
  120. Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: Is there a therapeutic role for elective neck dissection? Dermatol Surg 2007; 33(4): 410-20. doi: 10.1097/00042728-200704000-00003 PMID: 17430374
  121. Agrawal AD. Pharmacological activities of flavonoids: A review. Int J Pharm Sci Nanotechnol 2011; 4(2): 1394-8. doi: 10.37285/ijpsn.2011.4.2.3
  122. Saeidnia S, Abdollahi M. Antioxidants: Friends or foe in prevention or treatment of cancer: The debate of the century. Toxicol Appl Pharmacol 2013; 271(1): 49-63. doi: 10.1016/j.taap.2013.05.004 PMID: 23680455
  123. Stahl W, Sies H. Bioactivity and protective effects of natural carotenoids. Biochim Biophys Acta Mol Basis Dis 2005; 1740(2): 101-7. doi: 10.1016/j.bbadis.2004.12.006 PMID: 15949675
  124. Tanaka T, Shnimizu M, Moriwaki H. Cancer chemoprevention by carotenoids. Molecules 2012; 17(3): 3202-42. doi: 10.3390/molecules17033202 PMID: 22418926
  125. Lee JH, Kishikawa M, Kumazoe M, Yamada K, Tachibana H. Vitamin A enhances antitumor effect of a green tea polyphenol on melanoma by upregulating the polyphenol sensing molecule 67-kDa laminin receptor. PLoS One 2010; 5(6): e11051. doi: 10.1371/journal.pone.0011051 PMID: 20548792
  126. Feskanich D, Willett WC, Hunter DJ, Colditz GA. Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women. Br J Cancer 2003; 88(9): 1381-7. doi: 10.1038/sj.bjc.6600882 PMID: 12778065
  127. Uddin AN, Labuda I, Burns FJ. A novel mechanism of filaggrin induction and sunburn prevention by β-damascenone in Skh-1 mice. Toxicol Appl Pharmacol 2012; 265(3): 335-41. doi: 10.1016/j.taap.2012.08.035 PMID: 22982537
  128. Delmas D, Lançon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr Drug Targets 2006; 7(4): 423-42. doi: 10.2174/138945006776359331 PMID: 16611030
  129. Qiu Y, Yu T, Wang W, Pan K, Shi D, Sun H. Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening. Biochem Biophys Res Commun 2014; 448(1): 15-21. doi: 10.1016/j.bbrc.2014.04.024 PMID: 24735534
  130. Hamsa TP, Thejass P, Kuttan G. Induction of apoptosis by sulforaphane in highly metastatic B16F-10 melanoma cells. Drug Chem Toxicol 2011; 34(3): 332-40. doi: 10.3109/01480545.2010.538694 PMID: 21649489
  131. Davids LM, Kleemann B, Kacerovská D, Pizinger K, Kidson SH. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B 2008; 91(2-3): 67-76. doi: 10.1016/j.jphotobiol.2008.01.011 PMID: 18342534
  132. Zhang H, Samadi AK, Cohen MS, Timmermann BN. Antiproliferative withanolides from the Solanaceae: A structure–activity study. Pure Appl Chem 2012; 84(6): 1353-67. doi: 10.1351/PAC-CON-11-10-08 PMID: 24098060
  133. Mandlik Ingawale DS, Namdeo AG. Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. J Diet Suppl 2021; 18(2): 183-226. doi: 10.1080/19390211.2020.1741484 PMID: 32242751
  134. Greay S, Ireland D. Induction of necrosis and cell cycle arrest in murine cancer cell lines by Melaleuca alternifolia (tea tree) oil and terpinen-4-ol. Chemother Pharmacol 2010; 65: 877-88.
  135. Nigam N, Bhui K, Prasad S, George J, Shukla Y. 6-Gingerol induces reactive oxygen species regulated mitochondrial cell death pathway in human epidermoid carcinoma A431 cells. Chem Biol Interact 2009; 181(1): 77-84. doi: 10.1016/j.cbi.2009.05.012 PMID: 19481070
  136. Yoon TJ, Yoo YC, Kang TB, et al. Antitumor activity of the Korean Mistletoe Lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res 2003; 26(10): 861-7. doi: 10.1007/BF02980033 PMID: 14609136
  137. Ukiya M, Akihisa T, Yasukawa K, Tokuda H, Suzuki T, Kimura Y. Anti-inflammatory, anti-tumor-promoting, and cytotoxic activities of constituents of marigold (Calendula officinalis) flowers. J Nat Prod 2006; 69(12): 1692-6. doi: 10.1021/np068016b PMID: 17190444
  138. Ngo SNT, Williams DB, Head RJ. Rosemary and cancer prevention: Preclinical perspectives. Crit Rev Food Sci Nutr 2011; 51(10): 946-54. doi: 10.1080/10408398.2010.490883 PMID: 21955093
  139. Debnath S, Kumar S, Chandu AN, Bhattacharjee C. Cytotoxicity study of plant Aloe vera (Linn). Chron Young Sci 2012; 3(3): 233-5. doi: 10.4103/2229-5186.99595
  140. Priestap HA, Galvis A, Rivero N, Costantino V, Lopez LA, Barbieri MA. Dehydroleucodine and dehydroparishin-B inhibit proliferation and motility of B16 melanoma cells. Phytochem Lett 2012; 5(3): 581-5. doi: 10.1016/j.phytol.2012.05.018
  141. Lee CC, Chiu CC, Liao WT, et al. Alpinia oxyphylla Miq. bioactive extracts from supercritical fluid carbon dioxide extraction. Biochem Eng J 2013; 78: 101-7. doi: 10.1016/j.bej.2013.03.009
  142. Lo CY, Liu PL, Lin LC, et al. Antimelanoma and antityrosinase from Alpinia galangal constituents. ScientificWorldJournal 2013; 2013: 1-5. doi: 10.1155/2013/186505 PMID: 24027439
  143. Uzzaman S. Pharmacological activities of neem (Azadirachta indica): A review. Int J Pharmacog Life Sci 2020; 1(1): 38-41. doi: 10.33545/27072827.2020.v1.i1a.8
  144. Nagini S, Nivetha R, Palrasu M, Mishra R. Nimbolide, a neem limonoid, is a promising candidate for the anticancer drug arsenal. J Med Chem 2021; 64(7): 3560-77. doi: 10.1021/acs.jmedchem.0c02239 PMID: 33739088
  145. Dhama K, Sharun K, Gugjoo MB, et al. A comprehensive review on chemical profile and pharmacological activities of Ocimum basilicum. Food Rev Int 2023; 39(1): 119-47. doi: 10.1080/87559129.2021.1900230
  146. Ahmad B, Hafeez N, Rauf A, et al. Phyllanthus emblica: A comprehensive review of its therapeutic benefits. Front Pharmacol 2021; 138: 278-310.
  147. Santha S, Dwivedi C. Anticancer effects of sandalwood (Santalum album). Anticancer Res 2015; 35(6): 3137-45. PMID: 26026073
  148. Tiwari P, Nayak P, Prusty SK, Sahu PK. Phytochemistry and pharmacology of Tinospora cordifolia: A review. Syst Rev Pharm 2018; 9(1): 70-8. doi: 10.5530/srp.2018.1.14
  149. Burgeiro A, Bento AC, Gajate C, Oliveira PJ, Mollinedo F. Rapid human melanoma cell death induced by sanguinarine through oxidative stress. Eur J Pharmacol 2013; 705(1-3): 109-18. doi: 10.1016/j.ejphar.2013.02.035 PMID: 23499690
  150. Goldberg LH, Landau JM, Moody MN, Vergilis-Kalner IJ. Treatment of Bowen’s disease on the penis with low concentration of a standard mixture of solasodine glycosides and liquid nitrogen. Dermatol Surg 2011; 37(6): 858-61. doi: 10.1111/j.1524-4725.2011.02014.x PMID: 21605251
  151. Soliman E, Henderson KL, Danell AS, Van Dross R. Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: Role of cyclooxygenase-2 and novel J-series prostamides. Mol Carcinog 2016; 55(2): 117-30. doi: 10.1002/mc.22257 PMID: 25557612
  152. Blázquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006; 20(14): 2633-5. doi: 10.1096/fj.06-6638fje PMID: 17065222
  153. Dheeraj A, Rigby CM, O’Bryant CL, et al. Silibinin treatment inhibits the growth of Hedgehog inhibitor-resistant basal cell carcinoma cells via targeting EGFR-MAPK-Akt and Hedgehog signaling. Photochem Photobiol 2017; 93(4): 999-1007. doi: 10.1111/php.12727 PMID: 28120452
  154. Berlanda J, Kiesslich T, Oberdanner CB, Obermair FJ, Krammer B, Plaetzer K. Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol 2006; 25(1-2): 173-88. doi: 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.100 PMID: 16566716
  155. Gupta N, Gupta GD, Singh D. Localized topical drug delivery systems for skin cancer: Current approaches and future prospects. Front Nanotechnol 2022; 4: 1006628. doi: 10.3389/fnano.2022.1006628
  156. Shah K, Date A, Joshi M, Patravale V. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int J Pharm 2007; 345(1-2): 163-71. doi: 10.1016/j.ijpharm.2007.05.061 PMID: 17644288
  157. Ravikumar P, Tatke P. Advances in encapsulated dermal formulations in chemoprevention of melanoma: An overview. J Cosmet Dermatol 2019; 18(6): 1606-12. doi: 10.1111/jocd.13105 PMID: 31436386
  158. Slominski AT, Brożyna AA, Zmijewski MA, et al. Vitamin D signaling and melanoma: Role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97(6): 706-24. doi: 10.1038/labinvest.2017.3 PMID: 28218743
  159. Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015; 49(8): 907-37. doi: 10.1177/1060028015586218 PMID: 25991832
  160. Weinstein D, Leininger J, Hamby C, Safai B. Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol 2014; 7(6): 13-24. PMID: 25013535
  161. Vennepureddy A, Thumallapally N, Nehru VM, Atallah JP, Terjanian T. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res 2016; 8(2): 63-75. doi: 10.14740/jocmr2424w PMID: 26767073
  162. Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J 2012; 18(2): 192-202. doi: 10.1097/PPO.0b013e31824f118b PMID: 22453021

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers